Newsletter Signup | Community
Cancer Connect - Treatment of Recurrent Multiple Myeloma
Addition of Darzalex™ to Revlimd or Velcade based treatment regimen is new standard for transplant ineligible patients.
Stem Cell Transplant remains a major component in the treatment of newly diagnosed multiple myeloma.
TOURMALINE-MM3 clinical trials demonstrates Ninlaro can be used as maintenance therapy for multiple myeloma.
Empliciti combined with Revlimid or Pomalyst delays progression and prolongs survival in recurrent multiple myeloma.
Amgen releases initial data on AMG 420 Immunotherapy and the initial results in multiple myeloma look very good
New Antibody that targets CD74 on myeloma cells gets nod from FDA to proceed.
UK doctors identify a new target for treating Multiple Myeloma: